<DOC>
	<DOCNO>NCT02733991</DOCNO>
	<brief_summary>A premarket , international multicenter , prospective , open label , adaptive , randomize control study . The aim evaluate efficacy sensor augment pump therapy MiniMed™640G SmartGuard™in prevent hypoglycemic event comparison continuous subcutaneous insulin infusion therapy type 1 diabetes adult increase risk hypoglycemia . The primary objective demonstrate reduction mean number hypoglycemic event use MiniMed™640G system SmartGuard™ secondary objective aim evaluate difference glycemic parameter HbA1c .</brief_summary>
	<brief_title>Study MiniMed™ 640G Insulin Pump With SmartGuard™ Prevention Low Glucose Events Adults With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Age 2475 year old time screening . Diagnosed Type 1 diabetes ≥10 year prior screen . On pump therapy ≥ 6 month prior screen . Not Real Time continuous glucose monitoring ≥ 3 month prior screen . HbA1c value ≥5.8 % ≤10.0 % assess local lab ≤ 15 day prior screen perform screening . A document Severe Hypoglycemia event ≤ 12 month prior screen , OR Clarke score ≥4 assess time screening , OR Gold score ≥4 assess time screening . Subject willing sign date inform consent , comply study procedure wear study device require study . Untreated Addison 's disease , thyroid disorder , growth hormone deficiency , hypopituitarism definite gastroparesis , per investigator judgment . Subject use Pramlintide ( Symlin ) SGLT2 inhibitor , GLP agonist time screen . Renal failure define creatinine clearance &lt; 30 ml/min , assess local lab test ≤ 3 month screen perform screen local lab . Hearing vision impairment hinder perception glucose display alarm , otherwise incapable use study device , per investigator judgment . Current pregnancy intention conceive . Any unresolved adverse skin condition area sensor placement ( e.g . psoriasis , rash , Staphylococcus infection ) . Alcohol drug abuse , nicotine , per investigator judgment . Any disease condition may preclude patient participate study , per investigator judgment . Legally incompetent , illiterate vulnerable person . Randomization Criteria : If subject meet criterion , well follow criterion assessed end runin period , may continue participate treatment period study : Subject worn two week sensor transmitter runin period . Subject show acceptable tolerance sensor wear , per investigator judgment . Subject perform ≥ 4 finger stick blood glucose measurement daily , determine CareLink™ Clinical data upload mean number SMBG/day past 14 day ( SMBG number / day ≥ 3.5 round 4 ) . Subject show ability comprehend pump training study procedure , per investigator judgment .</criteria>
	<gender>All</gender>
	<minimum_age>24 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>